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Abstract
Background: Gut bifidobacteria are believed to influence immune-related diseases. The objective
of this study was to assess the possible relationships between the gut bifidobacteria composition
and coeliac disease (CD) in children.
A total of 48 faecal samples (30 and 18 samples from active and no active CD patients, respectively)
and 33 duodenal biopsy specimens of CD patients (25 and 8 samples from active and non-active
CD patients, respectively) were analysed. Samples (30 faecal samples and 8 biopsies) from a control
age-matched group of children were also included for comparative purposes. Gut Bifidobacterium
genus and species were analyzed by real-time PCR.
Results: Active and non-active CD patients showed lower numbers of total Bifidobacterium and B.
longum species in faeces and duodenal biopsies than controls, and these differences were
particularly remarkable between active CD patients and controls. B. catenulatum prevalence was
higher in biopsies of controls than in those of active and non-active CD patients, whereas B. dentium
prevalence was higher in faeces of non-active CD patients than in controls. Correlations between
levels of Bifidobacterium and B. longum species in faecal and biopsy samples were detected in both
CD patients and controls.
Conclusion: Reductions in total Bifidobacterium and B. longum populations were associated with
both active and non-active CD when compared to controls. These bacterial groups could
constitute novel targets for adjuvant dietary therapies although the confirmation of this hypothesis
would require further investigations.
Background
Coeliac disease (CD) is a chronic inflammatory disorder
of the small intestine that presents in genetically predis-
posed individuals following gluten consumption. Gluten
removal from the diet is currently the only treatment
available. This disease often presents in early childhood
with small intestinal villous atrophy and signs of malab-
sorption [1]. Recently, other factors than gluten such as
Published: 22 December 2008
BMC Microbiology 2008, 8:232 doi:10.1186/1471-2180-8-232
Received: 3 June 2008
Accepted: 22 December 2008
This article is available from: http://www.biomedcentral.com/1471-2180/8/232
© 2008 Collado et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Microbiology 2008, 8:232 http://www.biomedcentral.com/1471-2180/8/232imbalances in the intestinal microbiota have been
reported to be associated with CD [2-5]. Most of these
studies have been focused on faecal microbiota composi-
tion but less information is available on mucosa-associ-
ated microbiota of CD patients [2,5]. Neither possible
relation between faecal and duodenal bacterial popula-
tions has been reported in CD.
Bifidobacterium genus constitutes an important bacterial
group in the human gut, where this is thought to be essen-
tial to maintain health via beneficial metabolic, trophic,
and protective functions [6,7]. Bifidobacterium is the pre-
dominant intestinal bacterial genus during the first year of
life, particularly in full-term breastfed infants, although
becomes quantitatively less important in adult's microbi-
ota [8,9]. Qualitative and quantitative differences in Bifi-
dobacterium species composition have been related to the
development of inflammatory diseases such as allergy,
irritable bowel syndrome (IBS), inflammatory bowel dis-
eases (IBD) and colorectal cancer compared to healthy
controls [10-12]. In addition, different immunomodula-
tory properties have been attributed to different Bifidobac-
terium species and strains that in turn were related to
different disease risks. Strains of B. adolescentis have been
shown to be more proinfammatory or had non-effect on
immunity, while strains of the species B. bifidum and B.
longum were shown to have immunoregulatory properties
[13-15]. In this context, it has been suggested that Bifido-
bacterium strains colonizing the human gut could contrib-
ute to regulate disturbances in the balance of T-helper 1
(Th1)/Th2 lymphocyte responses to exogenous antigens
related to either allergic diseases (characterized by a Th2-
phenotype polarization) or Crohn and CD (characterized
by a Th1 phenotype polarization). As a consequence, Bifi-
dobacterium species have been regarded as particularly
attractive targets for dietary intervention within the gut
ecosystem to maintain intestinal homeostasis and host
health.
The objective of this study was to assess the Bifidobacterium
species composition of duodenal biopsies and faecal sam-
ples from CD patients (with active and non-active dis-
ease) and age-matched controls by the use of quantitative
real-time PCR technique to elucidate their possible role in
this disorder.
Methods
Subjects
Three groups of children were included in this study: (1)
active CD patients on a normal gluten-containing diet; (2)
non-active CD patients after following a gluten-free diet
for at least 2 years; and (3) control children without
known gluten intolerance. Biopsy specimens of the con-
trol group were obtained from children who were investi-
gated for weight loss, growth retardation or functional
intestinal disorders of non-coeliac origin, confirmed by
showing a normal villous structure after diagnosis by
biopsy examination.
The following faecal samples and duodenal biopsy speci-
mens from these group of subjects were included in the
analyses: 30 faecal and 25 biopsy samples from active CD
patients; 18 faecal and 8 biopsy samples from non-active
CD patients and 30 faecal and 8 biopsy samples from con-
trol children.
None of the children included in the study was treated
with antibiotics for at least 1 month before the sampling
time and they were recommended not consuming probi-
otic-containing products for at least 15 days prior the sam-
pling time to limit the detection of food-related
bifidobacteria without delaying too much the diagnosis
procedure. The adherence to this dietary recommendation
was checked at the sampling time and children that did
not comply with this recommendation were not included
in the study. The study protocol was approved by the local
committee on ethical practice from CSIC and Hospitals
taking part in the study. Children were enrolled in the
study after written informed consent was obtained from
their parents.
Sampling preparation and DNA extraction
Samples were collected from every subject in sterile plastic
recipients, frozen at -20°C immediately and kept at -80°C
until further processing. Duodenal biopsy specimens were
obtained by capsule and endoscopy after a 12-h fasting
period. Faeces (1 g) and duodenal biopsy samples (10–15
mg) were weighted, diluted 1:10 (w/v) in PBS (pH 7.2)
and homogenized by thorough agitation in a vortex. Aliq-
uots of these dilutions were used for DNA extraction.
DNA from both type of samples (faeces and biopsies) and
from pure cultures of the different bacterial strains used as
reference were extracted by using the QIAamp DNA stool
Mini kit (Qiagen, Hilden, Germany) following the manu-
facturer's instructions.
Real-time PCR (qPCR) analysis
Quantitative real time PCR was used to characterize the
faecal microbiota by using group and species-specific
primers described previously [16,17]. Briefly, PCR ampli-
fication and detection were performed with an ABI PRISM
7000-PCR sequence detection system (Applied Biosys-
tems, UK). Each reaction mixture of 25 μl was composed
of SYBR® Green PCR Master Mix (SuperArray Bioscience
Corporation, USA), 1 μl of each of the specific primers at
a concentration of 0.25 μM, and 1 μl of template DNA.
The fluorescent products were detected at the last step of
each cycle. A melting curve analysis was made after ampli-
fication to distinguish the targeted PCR product from the
non-targeted PCR product. Bacterial concentration fromPage 2 of 9
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obtained from standard curves. A standard curve was
made from serial dilutions of DNA isolated from each
pure culture of the different reference strains. A linear rela-
tionship was observed between the cell number and CT
values (r2 = 0.99–0.97) when the DNA was isolated from
cultures containing between 102 and 109 log cells/ml, as
determined by epifluorescence microscopy counts using
DAPI. The following reference strains were used to con-
struct the corresponding standard curves: Bifidobacterium
longum subsp. longum CECT 4503, B. longum subsp. infan-
tis CECT 4553, B. bifidum LMG 11041, B. breve LMG
11042, B. pseudocatenulatum CECT 5776, B. animalis
subsp. lactis DSMZ 10140, B. adolescentis LMG 11037, and
B. dentium CECT 687. The strains were obtained from the
Spanish Collection of Type Cultures (CECT), the German
Collection of Microorganisms and Cell Cultures (DSMZ)
and the Belgian Coordinated Collections of Microorgan-
isms (BCCM-LMG, University of Gent).
Statistical analyses
Statistical analyses were done using the SPSS 11.0 soft-
ware (SPSS Inc, Chicago, IL, USA). Due to non-normal
distribution, microbial data are expressed as medians with
interquartile ranges (IQR). Comparisons among data of
more than two groups of children were done by applying
the Kruskal-Wallis test and comparisons between data of
two groups of children were done by applying the Mann-
Whitney U test. The possible correlation between varia-
bles was studied by applying the Spearman rank correla-
tion coefficient and significance was established at 0.5%.
The chi-square test was used to establish differences in
species prevalence between the studied groups of chil-
dren. A P < 0.050 was considered statistically significant.
Bonferroni adjustment test was also applied to correct the
significance for a multiple test comparisons among three
groups (active and non-active CD patients and control
groups), which has the advantage of reducing type I error
and the disadvantage of increasing type II error.
Results
Subjects
Clinical characteristics of the children groups included in
the study are shown in Table 1. Relative representation of
males and females was almost equivalent in the study.
Active CD patients were on a normal gluten-containing
diet, showed clinical symptoms of the disease, positive
CD serology markers (anti-gliadin antibodies AGA and
anti-transglutaminase antibodies t-TG) and signs of severe
enteropathy by duodenal biopsy examination classified as
type 3 according to Marsh classification of CD [18]. Non-
active CD patients, who had been on a gluten-free diet for
at least 2 years, showed negative CD serology markers and
normal mucosa or infiltrative lesion classified as type 0–1
according to Marsh classification. A total of 30 faecal sam-
ples from 56.4 months old children, and 25 biopsies from
60.6 months old children were included in the active CD
patient group. A total of 18 faecal samples of 63.5 months
old children and 8 biopsies of 57.8 months old children
were included in the non-active CD patient group. Finally,
a total of 30 faecal samples of 45.0 months old children
and 8 biopsies of 49.2 months old children were included
in the control group for comparative purposes.
Table 1: Clinical characteristics of the studied subjects.
Characteristics Active CD Non-active CD Control
Number of patients 30 18 30
Age (average months and SD) 56.4 (38.5) 65.2 (37.7) 45.0 (33.5)
Gender
- male 12/30 (40.0%) 8/18 (44.4%) 13/30 (43.3%)
- female 18/30 (60.0%) 10/18 (55.6%) 17/30 (56.7%)
Clinical
- Abdominal 2/30 (6.6%) - -
- Diarrhoea 28/30 (93.4%) 2/18 (11.1%) -
- Weight loss 9/30 (30.0%) - -
- Anaemia 14/30 (46.6%) 8/18 (44.4%) -
Biochemical
- Asymptomatic 4/30 (13.3%) 18/18 (100%) -
- Iron deficiency 10/30 (33.3%) - -
Serology
AGA (anti-gliadin antibodies) AGA + (100%) AGA + (0%) AGA + (0%)
t-TG (anti-transglutaminase antibodies) t-TG + (100%) t-TG + (0%) t-TG + (0%)
Duodenal Biopsy a M3 (100%) M0-1 (100%) M0-1 (100%)
a Modified Marsh Classification of CD[18]. M0: Normal mucosa; CD highly unlikely. M01: (Infiltrative lesion): Seen in patients on a gluten-free diet 
(suggesting minimal amounts of gliadin are being ingested); patients with dermatitis herpetiformis (DH); and family members of patients with CD. 
M2 (Hyperplasic type): seen occasionally in DH. M3: > 40 Intraepithelial Lymphocytes per 100 Enterocytes, crypts increased and villi with atrophy 
(partial or complete villous atrophy).Page 3 of 9
(page number not for citation purposes)
BMC Microbiology 2008, 8:232 http://www.biomedcentral.com/1471-2180/8/232Duodenal Bifidobacterium species composition
B. longum was one of the most frequently detected species
in biopsy samples followed by B. breve, B. bifidum, B. cat-
enulatum and B. lactis (Table 2). Currently, the species B.
longum included B. longum subsp. longum, B. longum
subsp. infantis and B. longum subsp. suis, which were
quantified with the set of primers for the quoted species.
B. breve was significantly more prevalent in active CD
patients than in non-active CD patients and controls
although the differences were not significant (P > 0.05). B.
catenulatum group was detected more frequently in con-
trols than in active CD (P = 0.050) and non-active CD
patients (P = 0.038). In addition, B. lactis group was
detected more frequently in active CD patients (P = 0.003)
and in controls (P = 0.012) than in non-active CD
patients. B. dentium was found in active CD and non-
active CD patients but not in controls. The prevalence of
B. lactis group was also significantly different in active CD
patients and controls as compared to that of non-active
CD patients by applying the Bonferroni adjustment, but
this was not the case for the rest of bacterial groups.
The composition of biopsy-associated bifidobacteria
assessed by qPCR is shown in Table 3. The most predom-
inant bifidobacterial species detected in biopsy samples
were B. longum, followed by B. breve, B. lactis, B. bifidum
Table 2: Prevalence of Bifidobacterium group and species in faeces and duodenal biopsies of children
Microbial group in 
biopsy samples
Prevalence (%)a P-value Chi-square test Bonferroni adjustment
Active CD 
(n = 25)
Non-active CD 
(n = 8)
Control (n = 8) Active- non-active 
CD
Control- active 
CD
Control- non-
active CD
Bifidobacterium 
group
100.0 (25/25) 100.0 (8/8) 100.0 (8/8) - - -
B. longum 100.0 (25/25) 100.0 (8/8) 100.0 (8/8) - - -
B. breve 64.0 (16/25) 37.5 (3/8) 37.5 (3/8) 0.181 0.181 0.695
B. bifidum 52.0 (13/25) 25.0 (2/8) 37.5 (3/8) 0.180 0.380 0.500
B. adolescentis 36.0 (9/25) 12.5 (1/8) 25.0 (2/8) 0.380 0.669 0.500
B. catenulatum 
group
52.0 (13/25) 37.5 (3/8) 87.5 (7/8) 0.381 0.050* 0.038*
B. angulatum 32.0 (8/25) 12.5 (1/8) 50.0 (4/8) 0.277 0.419 0.282
B. lactis 60.0 (15/25) 0.0 (0/8) 62.5 (5/8) 0.003*, i 0.618 0.012*, i
B. longum subsp. 
infantis
0.0 (0/25) 0.0 (0/8) 0.0 (0/8) - - -
B. dentium 8.0 (2/25) 12.5 (1/8) 0.0 (0/8) 0.578 0.568 0.500
Microbial group in 
faecal samples
Prevalence (%)a P-value Chi-square test Bonferroni adjustment
Active CD 
(n = 30)
Non-active CD 
(n = 18)
Control (n = 30) Active- non-active 
CD
Control- active 
CD
Control- non-
active CD
Bifidobacterium 
group
100.0 (30/30) 100.0 (18/18) 100.0 (30/30) - - -
B. longum 100.0 (30/30) 100.0 (18/18) 100.0 (30/30) - - -
B. breve 80.0 (24/30) 66.7 (12/18) 66.7 (20/30) 0.325 0.500 0.751
B. bifidum 100.0 (30/30) 100.0 (18/18) 100.0 (30/30) - - -
B. adolescentis 50.0 (15/30) 83.3 (15/18) 40.0 (12/30) 0.016*, i 0.452 0.045*
B. catenulatum 
group
100.0 (30/30) 100.0 (18/18) 100.0 (30/30) - - -
B. angulatum 20.0 (6/30) 16.7 (3/18) 23.0 (7/30) 0.546 0.601 0.521
B. lactis 56.7 (17/30) 61.1 (11/18) 63.3 (19/30) 0.502 0.975 0.775
B. longum subsp. 
infantis
36.7 (11/30) 22.2 (4/18) 36.7 (11/30) 0.351 0.795 0.532
B. dentium 13.3 (4/30) 27.7 (5/18) 6.6 (2/30) 0.265 0.407 0.040*
a Prevalence (Pr) reflects the number of positive amplifications from total samples analysed by PCR (n = number of samples analysed)
* Statistical differences were calculated by using Chi-square test 2 × 2. Significantly difference between groups was consider at P < 0.050
i Statistical differences were corrected for a multiple comparison test (3 variable) by using Bonferroni adjustment. Significantly difference between 
groups was considered at P < 0.017.Page 4 of 9
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B. dentium were less prevalent.
Significant differences were detected by using the Kruskal-
Wallis test among active and non-active CD patient and
control groups for total Bifidobacterium (P = 0.040), B.
longum (P = 0.017), B. breve (P = 0.018) and B. bifidum (P
= 0.022). No differences were found for the other ana-
lysed species. Comparisons of bifidobacterial levels
between groups by using the Mann-Whitney U test
allowed the detection of significantly higher levels of total
Bifidobacterium in controls than in active CD patients (P =
0.009), although no significant differences were found
between non-active CD patients and controls (P = 0.461).
B. longum levels were also significantly higher in controls
than in active CD patients (P = 0.004) and slightly higher
Table 3: Bifidobacterium group and species of faeces and duodenal biopsies from children quantified by qPCR.
Microbial group in 
biopsy samples
Bacterial countsa (Log cells/g) P-value Mann-Whitney/Test Bonferroni adjustment
Active CD (n = 25) Non-active CD (n = 8) Control (n = 8) Active- non-
active CD
Control- active 
CD
Control- non-
active CD
Median IQR Median IQR Median IQR
Bifidobacterium 
group
5.95 5.55–6.21 6.15 4.97–6.28 6.27 6.03–6.80 0.604 0.009*, i 0.461
B. longum 4.66 4.36–5.37 4.95 4.90–5.60 5.60 5.33–5.73 0.310 0.004*, i 0.368
B. breve 5.14 4.59–5.46 3.05 3.02–3.50 5.21 5.00–5.80 0.020* 0.630 0.100
B. bifidum 4.35 3.40–4.75 3.98 2.15–4.44 4.17 3.48–4.66 0.800 0.700 0.950
B. adolescentis 3.22 2.86–3.74 3.06 - 3.87 1.80–3.30 0.600 0.327 0.667
B. catenulatum 
group
4.08 3.16–4.60 4.12 4.04–4.53 4.10 3.76–4.46 0.736 0.757 0.660
B. angulatum 2.95 1.54–3.80 4.10 - 3.55 1.58–4.44 0.275 0.933 0.900
B. lactis 6.33 5.50–6.18 - - 5.28 4.59–5.70 - 0.033* -
B. longum subsp. 
infantis
- - - - - - - - -
B. dentium 4.23 3.45–5.23 4.00 - - - 0.627 - -
Microbial group in 
faecal samples
Bacterial countsa (Log cells/g) P-value Mann-Whitney test Bonferroni adjustment
Active CD (n = 30) Non-active CD (n = 18) Control (n = 30) Active- non-
active CD
Control- active 
CD
Control- non-
active CD
Median IQR Median IQR Median IQR
Bifidobacterium 
group
9.67 8.68–9.90 8.77 8.58–9.60 9.80 9.23–10.33 0.183 0.014*, i 0.002*, i
B. longum 8.90 8.56–9.40 8.30 7.78–9.00 9.28 8.88–10.10 0.030* 0.038* < 0.001*, i
B. breve 6.97 5.56–7.82 4.02 3.08–5.15 6.94 6.18–8.02 < 0.001*, i 0.860 < 0.001*, i
B. bifidum 7.64 6.42–8.16 6.74 6.40–6.87 6.96 6.67–7.93 0.030* 0.577 0.050*
B. adolescentis 6.95 5.55–7.92 5.40 4.93–7.76 5.97 5.37–6.60 0.112 0.050* 0.633
B. catenulatum 
group
7.16 6.50–8.68 7.84 7.07–8.50 7.65 7.56–8.42 0.425 0.106 0.758
B. angulatum 4.96 4.64–7.20 4.68 4.24–5.07 4.65 4.12–5.00 0.548 0.153 0.569
B. lactis 7.12 5.30–7.45 5.17 4.66–7.20 5.45 4.66–7.07 0.175 0.081 0.780
B. longum subsp. 
infantis
6.57 5.80–7.76 7.47 6.83–7.82 6.68 6.45–7.06 0.192 0.341 0.117
B. dentium 6.28 6.10–6.30 5.24 4.66–5.82 5.20 3.86–5.30 0.111 0.133 0.571
a Data are shown as medians and interquartile range (IQR) of cell number per gram of faecal or duodenal biopsy sample.
* Statistical differences were calculated by using Mann-Whitney U test comparing two variables. Significantly difference between groups was 
considered at P < 0.050.
i Statistical differences were corrected for a multiple comparison test (3 variable) by using Bonferroni adjustment. Significantly difference between 
groups was considered at P < 0.017.Page 5 of 9
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(P = 0.368). Total Bifidobacterium and B. longum group lev-
els were also significantly different between active CD and
control children by applying the Bonferroni adjustment.
B. breve levels were significantly lower in non-active CD
patients than in active CD patients (P = 0.020) and also
slightly lower (P = 0.100) than in control children as it
was the case for faeces. A similar trend was found for B.
bifidum but none of the differences reached statistical sig-
nificance. B. lactis levels were higher in active CD patients
than in controls (P = 0.033), while this species was not
detected in non-active CD patients.
Faecal Bifidobacterium species composition
The number of positive samples for Bifidobacterium group
and species detected by PCR (prevalence) compared to the
total number of samples tested in the study are shown in
Table 2. B. longum, B. bifidum and B. catenulatum groups
were detected in all faecal samples, whereas the other Bifi-
dobacterium species analysed were not detected in every
sample (Table 2). B. breve was detected more frequently in
active CD patients than non-active CD patients and con-
trols, although the differences were not significant (P >
0.05). B. adolescentis was detected more frequently in non-
active CD patients than in active CD patients (P = 0.016)
and controls (P = 0.045). B. dentium was significantly
more prevalent in non-active CD patients than in controls
(P = 0.040), and the same trend was detected between
active CD patients and controls but the differences were
not statistically significant. B. adolescentis prevalence was
also significantly different between non-active CD
patients and active CD patients (P = 0.016) by applying
the Bonferroni adjustment test. No significant differences
were found for the other Bifidobacterium groups or species.
The bacterial composition of faecal samples from the
three groups of children under study assessed by qPCR is
shown in Table 3. The most predominant Bifidobacterium
groups present in faecal samples were B. longum, B. catenu-
latum group and B. bifidum. Significant differences were
obtained by using the Kruskal-Wallis test among active
and non-active CD patient and control groups for total
Bifidobacterium (P = 0.002), B. longum (P < 0.001), B. breve
(P < 0.001), B. bifidum (P = 0.030) and B. adolescentis (P =
0.020). No differences were found for the other studied
species. The comparison of bifidobacterial levels between
groups by using the Mann-Whitney U test allowed the
detection of significant differences in several cases. Total
Bifidobacterium levels were significantly higher in control
samples than in those of active CD (P = 0.014) and non-
active CD patients (P = 0.002). No differences were found
between active and non-active CD patients (P = 0.183). B.
longum levels were significantly higher in controls than in
active CD (P = 0.038) and non-active CD patients (P <
0.001); moreover, B. longum levels were significantly
higher in non-active CD patients than in active CD
patients (P = 0.030). Most of these differences were also
statistically significant by applying the Bonferroni adjust-
ment at P < 0.017 (Table 3). B. breve levels were signifi-
cantly higher in active CD (P = 0.001) and control
children (P < 0.001) than in non-active CD patients,
which showed the lowest counts of this species, but differ-
ences between active CD patients and controls (P = 0.860)
were not found by either Mann Whitney or Bonferroni
adjustment test. Similarly, B. bifidum levels were higher in
active CD patients (P = 0.030) and controls (P = 0.050)
than in non-active CD patients, whereas significant differ-
ences were not found between active CD and control chil-
dren (P = 0.577). B. adolescentis levels were significantly
higher (P = 0.050) in active CD patients than in controls
while differences were not found neither between active
and non-active CD patients nor between non-active CD
patients and controls. However, differences in B. bifidum
and B. adolescentis were not statistically significant when
applying the Bonferroni adjustment test. No differences
were found for any other Bifidobacterium species analysed
between the three groups of children under study (Table
3).
Relationships between duodenal and faecal 
Bifidobacterium species composition
Faecal samples showed higher numbers (P < 0.050) of
bifidobacteria than duodenal biopsies samples for every
analyzed group, as anticipated (Fig. 1). Correlations were
generally found between levels of each bifidobacterial
group detected in faecal and biopsy samples within the
same individual. Thus, low faecal bifidobacterial levels
corresponded to low biopsy bifidobacterial levels in the
same subjects and vice versa. Correlations between total
Bifidobacterium levels in faecal and biopsy samples were
significant in active CD patients (R = 0.84, P < 0.001),
non-active CD patients (R = 0.67, P = 0.001) and controls
(R = 0.68, P < 0.001). Similarly, correlations between B.
longum levels in faecal and biopsy samples were signifi-
cant in active CD patients (R = 0.80, P < 0.001), non-
active CD patients (R = 0.79, P < 0.001) and controls (R =
0.53, P = 0.001). In active CD patients, correlations were
also found for B. breve (R = 0.44, P = 0.001), B. bifidum (R
= 0.52, P = 0.001), B. adolescentis (R = 0.57, P = 0.002), B.
catenulatum (R = 0.70, P < 0.001) and B. lactis (R = 0.70, P
< 0.001), whereas no correlations were found for B. angu-
latum, B. longum subsp.infantis and B. dentium. In controls,
significant correlations between bifidobacterial levels in
faeces and biopsy samples were also found for B. catenula-
tum group (R = 0.40, P = 0.017) and B. longum
subsp.infantis (R = 0.54, P = 0.030) and in non-active CD
patients for B. bifidum (R = 0.54, P = 0.012) and B. catenu-
latum group (R = 0.70, P = 0.001).Page 6 of 9
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Bifidobacterium species are regarded as key biological
markers of a healthy gut. Herein, features of the composi-
tion of this bacterial genus in the gut ecosystem of CD
patients, with active and non-active disease, and control
children have been reported for the first time, and the
existing correlations between faecal and duodenal biopsy-
associated bifidobacteria. Active and non-active CD
patients showed lower numbers of total Bifidobacterium in
both types of samples analysed, faeces and duodenal
biopsy specimens. These differences were significant in
every case except for biopsy samples of non-active CD
patients and controls. A similar trend was obtained by
using the Bonferroni adjustment test although differences
in faecal B. longum levels between control children and
active CD patients were not significant. Faecal imbalances
in total Bifidobacterium levels were detected in both active
and non-active CD patients as compared to controls and
therefore they seemed to be irrespectively of disease activ-
ity. However, duodenal Bifidobacterium levels seemed to
be partially restored after the gluten-free diet since signifi-
cant differences were not found between non-active CD
patients and control children. These different trends could
be a consequence of the limited number of biopsy sam-
ples available when compared with faecal samples. Bifido-
bacterium numbers of the mucosa of IBD patients and
allergic infants were also found to be reduced compared
to controls [10,19,20]. Some reports also showed that
Correlations of bifidobacterial groups of faecal and duodenal biopsy samples from all children (active and non-active CD patients and c ntrols) under studyFigure 1
Correlations of bifidobacterial groups of faecal and duodenal biopsy samples from all children (active and non-
active CD patients and controls) under study. Data represent the positive samples. The line in the box is the median 
(50% percentile), with the lower line the lower 25% border (25% percentile) and the upper line the 75% (75% percentile) bor-
der. The end of the upper vertical line is the maximum data value, outliers not considered. The end of the lower vertical line is 
the lowest value, outliers not considered. The separate dots or asterisks indicate outliers. Significant differences (P < 0.050) 
were found between faeces and biopsy levels of every bifidobacterial group analysed when considering all subjects.
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BMC Microbiology 2008, 8:232 http://www.biomedcentral.com/1471-2180/8/232allergic infants were colonized by bifidobacteria less often
and at lower concentrations than controls [9,10,21,22]. A
significant reduction of gut bifidobacterial levels was also
reported to precede the development of atopic diseases,
indicating a relation between relative abundance of this
bacterial genus and the development of immune-related
disorders [10]. A recent report also indicated that high
numbers of bifidobacteria may correlate positively with
the normalization of inflammatory status and improved
glucose tolerance and glucose-induced insulin secretion
in an obesity animal model induced by a high-fat contain-
ing diet [23]. These findings, together with the present
results, suggest that lower numbers of total bifidobacteria
may be associated with inflammatory processes, support-
ing the hypothesis that bifidobacteria are required to
maintain intestinal homeostasis.
The most predominant bifidobacterial groups detected in
both, biopsies and faeces, were B. longum, B. bifidum and
B. catenulatum followed by B. breve and B. lactis. In agree-
ment with previous studies, B. longum was the species
most commonly found in the faecal and duodenal
mucosa-associated microbiota [9,12]. The levels of B.
longum were markedly lower in active CD patients and to
a lesser extent in non-active CD patients than in controls
in both faecal and biopsy samples according with the data
obtained for total Bifidobacterium; the differences were sig-
nificant in every case except for biopsy samples of non-
active CD patients and controls presumably due to their
limited number. Imbalances in B. longum levels were
found irrespectively of the phase of the disease (active or
non-active) particularly in faeces; however, the gluten-free
diet could also influence the levels of this species since dif-
ferences were found between active and non-active CD
patients. Duodenal B. longum levels seemed to be partially
restored after the gluten-free diet, following the same
trend as that detected for total Bifidobacterium levels.
Bifidobacteria have been demonstrated to have a species
and strain-specific influence on immunity [14,15,24].
Strains of the genus Bifidobacterium have been shown to
polarized Th2/Th1 responses in a specific manner,
thereby modulating unbalanced cytokine production
characteristic of either Th2-type (e.g. allergy) or Th1-type
diseases (e.g. Crohn disease and CD) and overall inflam-
mation [13,25]. It has been speculated that typical adult-
type bifidobacterial species such as B. adolescentis and B.
catenulatum group could favour Th2-biased immune
responses characteristic of allergy inflammation [14]. In
contrast, anti-inflammatory properties have been gener-
ally attributed to strains of the species B. longum mainly
related to their ability to stimulate regulatory cytokine
production (e.g. IL-10) [25,26]. In this study, the higher
levels of B. longum detected in control samples (biopsies
and faeces) compared to those found in active and non-
active CD patient samples suggest that this bifidobacterial
group could exert a protective role in CD. Otherwise,
changes in the intestinal environment of CD patients,
such as the mucus layer composition, could secondarily
lead to changes in gut bacterial populations. In this con-
text, lower levels of B. longum have also been reported in
IBD and colorectal cancer patients [12].
B. breve and B. bifidum numbers were particularly reduced
in non-active CD patients when compared with active
CD-patients and controls in both biopsy specimens, and
especially in faecal samples, indicating that these reduc-
tions could be due to the gluten-free diet rather than to the
disease.
B. adolescentis were detected in slightly higher numbers in
faecal samples of active CD patients than in controls and
its prevalence was also higher in faeces of non-active CD
patients than in those of controls. However, this loosely
association between B. adolescentis and CD was neither
confirmed in biopsies nor in a preliminary study carried
out previously in a few faecal samples of active CD
patients and controls by PCR-DGGE [7].
In general, this study confirms that the dominant bifido-
bacterial species detected in faeces represented those
found in duodenal biopsies although in different quanti-
ties (Fig. 1), supporting previous reports on adults and
infants [27,28]. Significant correlations were detected
between levels of total Bifidobacterium and the species B.
longum in faecal and biopsy samples, which were the bac-
terial groups most clearly related to CD. Therefore, faecal
alterations of Bifidobacterium and B. longum levels reflect
those occurring in the duodenum. These could be used as
indexes of CD in faeces without the use of invasive biopsy
techniques, although further studies should be carried out
in other population groups to confirm such hypothesis.
Conclusion
Active and non-active CD is associated with changes in
number, composition and prevalence of Bifidobacterium
populations. The microbiota of CD patients is character-
ised by reductions in total Bifidobacterium and B. longum
numbers. These microbial deviations are not completely
restored after treatment with a gluten-free diet. Thus, the
results suggest that total and specific Bifidobacterium spe-
cies could be possible protective factors for CD. Therefore,
the administration of specific probiotics and prebiotics to
increase their intestinal levels could constitute a possible
adjuvant therapeutic strategy for this disorder. Confirma-
tion of such hypothesis would require further investiga-
tions.Page 8 of 9
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